- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | LYTIX BIOPHARMA ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab | 1 | Cision News | ||
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 21.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances | 2 | Cision News | ||
| 15.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma: Invitation to the Q1 2026 Results Presentation | 1 | Cision News | ||
| 06.05. | LYTIX BIOPHARMA ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma | 19 | Cision News | ||
| 21.04. | Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 | 1 | Cision News | ||
| 21.04. | Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma | 7 | Cision News | ||
| 16.04. | Lytix Biopharma ASA - Conversion to public limited liability company and name change registered | 1 | Cision News | ||
| 14.04. | Lytix Biopharma AS: Minutes from Annual General Meeting | 1 | Cision News | ||
| 09.04. | Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS | 1 | Cision News | ||
| 07.04. | Lytix Biopharma Names Renée Christine Amundsen COO With Immediate Effect | 1 | RTTNews | ||
| 07.04. | LYTIX BIOPHARMA AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth | 1 | Cision News | ||
| 25.03. | Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 | 6 | Cision News | ||
| 24.03. | Lytix Biopharma AS: Annual Report for 2025 | 2 | Cision News | ||
| 18.03. | LYTIX BIOPHARMA AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 | 4 | Cision News | ||
| 24.02. | Lytix Biopharma AS - New share capital registered | 3 | Cision News | ||
| 17.02. | LYTIX BIOPHARMA AS: Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) | 3 | Cision News | ||
| 12.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 1.360 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 0,980 | +5,38 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| NOVOGENIA | 5,950 | -0,83 % | Novogenia baut neuen Standort in Hallwang | Die Novogenia AG hat mit dem Spatenstich den Bau ihrer neuen Firmenzentrale im österreichischen Hallwang begonnen. Auf mehr als 9.300 Quadratmetern entstehen dort Laborflächen, Produktionskapazitäten... ► Artikel lesen | |
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| QIAGEN | 37,290 | -0,98 % | Qiagen-Aktie: Jetzt auf Fünfmonatshoch - lohnt sich der Einstieg? | Qiagen-Aktien legen heute kräftig zu. An der Frankfurter Börse kletterten die Papiere des Diagnostikspezialisten um 4 Prozent nach oben und markierten damit den höchsten Stand seit fünf Monaten. Der... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | +0,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | -0,02 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | +0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | +0,05 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | +0,06 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | +0,09 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen |
LYTIX BIOPHARMA ASA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,718 Euro und damit +0,84 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA ASA finden Sie auf Wallstreet Online.